Prediction of pre-eclampsia

Leslie Myatt, Lavenia B. Carpenter

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Summary Pre-eclampsia is associated with significant maternal and fetal morbidity and mortality worldwide. While provision of adequate antenatal care would significantly reduce morbidity and mortality in third-world countries, in first-world countries efforts are being focused on identification of at-risk patients and on targeted therapies. Pre-eclampsia can be distinguished as early (34 weeks) onset phenotypes. While these have been thought traditionally to be synonymous with severe and mild disease phenotypes, respectively, recent analyses show that an appreciable amount of severe disease is also late onset. There is evolving evidence that there are different underlying etiologies that ultimately lead to this syndrome defined by hypertension, proteinuria and edema. It is unlikely that one single biomarker will identify all individuals destined to develop pre-eclampsia. Rather, panels of biomarkers specific for the different phenotypes may identify those at risk for pre-eclampsia prior to the appearance of overt disease. Importantly, these measurements may also provide different (biochemical) definitions of disease. In order to have a significant impact on clinical or economic outcome it is vital to identify women who will develop early onset disease or severe disease, as these phenotypes are those associated with significant morbidity and mortality. Similarly, therapies must be targeted at these same outcomes and not just the appearance of hypertension and proteinuria at term. While there is abundant evidence in the literature for changes in expression or concentration of many biomarkers in established disease, there is still a dearth of prospective studies with well-defined clinical outcomes in which prospective measurement of biomarkers have been made.

Original languageEnglish (US)
Title of host publicationPre-Eclampsia: Etiology and Clinical Practice
PublisherCambridge University Press
Pages215-231
Number of pages17
ISBN (Print)9780511545634, 052183189X, 9780521831895
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Pre-Eclampsia
Biomarkers
Phenotype
Morbidity
Proteinuria
Hypertension
Fetal Mortality
Prenatal Care
Mortality
Developing Countries
Edema
Economics
Mothers
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Myatt, L., & Carpenter, L. B. (2007). Prediction of pre-eclampsia. In Pre-Eclampsia: Etiology and Clinical Practice (pp. 215-231). Cambridge University Press. https://doi.org/10.1017/CBO9780511545634.016

Prediction of pre-eclampsia. / Myatt, Leslie; Carpenter, Lavenia B.

Pre-Eclampsia: Etiology and Clinical Practice. Cambridge University Press, 2007. p. 215-231.

Research output: Chapter in Book/Report/Conference proceedingChapter

Myatt, L & Carpenter, LB 2007, Prediction of pre-eclampsia. in Pre-Eclampsia: Etiology and Clinical Practice. Cambridge University Press, pp. 215-231. https://doi.org/10.1017/CBO9780511545634.016
Myatt L, Carpenter LB. Prediction of pre-eclampsia. In Pre-Eclampsia: Etiology and Clinical Practice. Cambridge University Press. 2007. p. 215-231 https://doi.org/10.1017/CBO9780511545634.016
Myatt, Leslie ; Carpenter, Lavenia B. / Prediction of pre-eclampsia. Pre-Eclampsia: Etiology and Clinical Practice. Cambridge University Press, 2007. pp. 215-231
@inbook{cd9043f232a749b28f6759edcf2b9cc3,
title = "Prediction of pre-eclampsia",
abstract = "Summary Pre-eclampsia is associated with significant maternal and fetal morbidity and mortality worldwide. While provision of adequate antenatal care would significantly reduce morbidity and mortality in third-world countries, in first-world countries efforts are being focused on identification of at-risk patients and on targeted therapies. Pre-eclampsia can be distinguished as early (34 weeks) onset phenotypes. While these have been thought traditionally to be synonymous with severe and mild disease phenotypes, respectively, recent analyses show that an appreciable amount of severe disease is also late onset. There is evolving evidence that there are different underlying etiologies that ultimately lead to this syndrome defined by hypertension, proteinuria and edema. It is unlikely that one single biomarker will identify all individuals destined to develop pre-eclampsia. Rather, panels of biomarkers specific for the different phenotypes may identify those at risk for pre-eclampsia prior to the appearance of overt disease. Importantly, these measurements may also provide different (biochemical) definitions of disease. In order to have a significant impact on clinical or economic outcome it is vital to identify women who will develop early onset disease or severe disease, as these phenotypes are those associated with significant morbidity and mortality. Similarly, therapies must be targeted at these same outcomes and not just the appearance of hypertension and proteinuria at term. While there is abundant evidence in the literature for changes in expression or concentration of many biomarkers in established disease, there is still a dearth of prospective studies with well-defined clinical outcomes in which prospective measurement of biomarkers have been made.",
author = "Leslie Myatt and Carpenter, {Lavenia B.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511545634.016",
language = "English (US)",
isbn = "9780511545634",
pages = "215--231",
booktitle = "Pre-Eclampsia: Etiology and Clinical Practice",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Prediction of pre-eclampsia

AU - Myatt, Leslie

AU - Carpenter, Lavenia B.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Summary Pre-eclampsia is associated with significant maternal and fetal morbidity and mortality worldwide. While provision of adequate antenatal care would significantly reduce morbidity and mortality in third-world countries, in first-world countries efforts are being focused on identification of at-risk patients and on targeted therapies. Pre-eclampsia can be distinguished as early (34 weeks) onset phenotypes. While these have been thought traditionally to be synonymous with severe and mild disease phenotypes, respectively, recent analyses show that an appreciable amount of severe disease is also late onset. There is evolving evidence that there are different underlying etiologies that ultimately lead to this syndrome defined by hypertension, proteinuria and edema. It is unlikely that one single biomarker will identify all individuals destined to develop pre-eclampsia. Rather, panels of biomarkers specific for the different phenotypes may identify those at risk for pre-eclampsia prior to the appearance of overt disease. Importantly, these measurements may also provide different (biochemical) definitions of disease. In order to have a significant impact on clinical or economic outcome it is vital to identify women who will develop early onset disease or severe disease, as these phenotypes are those associated with significant morbidity and mortality. Similarly, therapies must be targeted at these same outcomes and not just the appearance of hypertension and proteinuria at term. While there is abundant evidence in the literature for changes in expression or concentration of many biomarkers in established disease, there is still a dearth of prospective studies with well-defined clinical outcomes in which prospective measurement of biomarkers have been made.

AB - Summary Pre-eclampsia is associated with significant maternal and fetal morbidity and mortality worldwide. While provision of adequate antenatal care would significantly reduce morbidity and mortality in third-world countries, in first-world countries efforts are being focused on identification of at-risk patients and on targeted therapies. Pre-eclampsia can be distinguished as early (34 weeks) onset phenotypes. While these have been thought traditionally to be synonymous with severe and mild disease phenotypes, respectively, recent analyses show that an appreciable amount of severe disease is also late onset. There is evolving evidence that there are different underlying etiologies that ultimately lead to this syndrome defined by hypertension, proteinuria and edema. It is unlikely that one single biomarker will identify all individuals destined to develop pre-eclampsia. Rather, panels of biomarkers specific for the different phenotypes may identify those at risk for pre-eclampsia prior to the appearance of overt disease. Importantly, these measurements may also provide different (biochemical) definitions of disease. In order to have a significant impact on clinical or economic outcome it is vital to identify women who will develop early onset disease or severe disease, as these phenotypes are those associated with significant morbidity and mortality. Similarly, therapies must be targeted at these same outcomes and not just the appearance of hypertension and proteinuria at term. While there is abundant evidence in the literature for changes in expression or concentration of many biomarkers in established disease, there is still a dearth of prospective studies with well-defined clinical outcomes in which prospective measurement of biomarkers have been made.

UR - http://www.scopus.com/inward/record.url?scp=84861629910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861629910&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511545634.016

DO - 10.1017/CBO9780511545634.016

M3 - Chapter

AN - SCOPUS:84861629910

SN - 9780511545634

SN - 052183189X

SN - 9780521831895

SP - 215

EP - 231

BT - Pre-Eclampsia: Etiology and Clinical Practice

PB - Cambridge University Press

ER -